The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Consensus on molecular imaging and theranostics in neuroendocrine neoplasms
Open accessAbstract
Nuclear medicine plays an increasingly important role in the management neuroendocrine neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission tomography/computed tomography (PET/CT) and peptide receptor radionuclide therapy (PRRT) have been used in clinical trials and approved by the European Medicines Agency and Food and Drug Administration. EANM Focus 3 performed a multi-disciplinary Delphi process to deliver a balanced perspective on molecular imaging and radionuclide therapy in well-differentiated neuroendocrine tumours (NET). Several societies’ guidelines address NEN management, however, many issues are still debated, due to both the difficulty in acquiring strong clinical evidence in a rare and heterogeneous disease and the different availability of diagnostic and therapeutic options across countries. EANM Focus 3 reached consensus on employing [68Ga]Ga-DOTA-SSA PET/CT with diagnostic CT or magnetic resonance imaging for unknown primary NET detection, metastatic NET, NET staging/restaging, suspected extra-adrenal pheochromocytoma/paraganglioma and suspected paraganglioma. Consensus was reached on employing [18F]FDG PET/CT in neuroendocrine carcinoma, G3 NET and in G1–2 NET with mismatched lesions (CT-positive/[68Ga]Ga-DOTA-SSA-negative). PRRT was recommended for second line treatment for gastrointestinal NET with [68Ga]Ga-DOTA-SSA uptake in all lesions, in G1/G2 NET at disease progression, and in a subset of G3 NET provided all lesions are positive at [18F]FDG and [68Ga]Ga-DOTA-SSA. PRRT rechallenge may be used for in patients with stable disease for at least one year after therapy completion. An international consensus is not only a prelude to a more standardized management across countries but also serves as a guide for the direction to follow when designing new research studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., Bossuyt, P. M. M., & the QUADAS-2 Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00009 · Cited by 14,199
Shea, B. J., Reeves, B. C., Wells, G., Thuku, M., Hamel, C., Moran, J., Moher, D., Tugwell, P., Welch, V., Kristjansson, E., et al. (2017) · BMJ · doi:10.1136/bmj.j4008 · Cited by 10,636
Research guidelines for the Delphi survey technique
Hasson, F. (2000) · Journal of Advanced Nursing · doi:10.1046/j.1365-2648.2000.01567.x · Cited by 5,951
Pheochromocytoma and Paraganglioma
Neumann, H. P. H., Young, W. F., & Eng, C. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1806651 · Cited by 736
ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum
Niederle, B., Pape, U.-F., Costa, F., Gross, D., Kelestimur, F., Knigge, U., Öberg, K., Pavel, M., Perren, A., Toumpanakis, C., et al. (2016) · Neuroendocrinology · doi:10.1159/000443170 · Cited by 474
Self-citationSomatostatin receptor antagonists for imaging and therapy.
Fani, M., Nicolas, G. P., & Wild, D. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.186783 · Cited by 274
Garske-Román, U., Sandström, M., Fröss Baron, K., Lundin, L., Hellman, P., Welin, S., Johansson, S., Khan, T., Lundqvist, H., Eriksson, B., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-3945-z · Cited by 254
Self-citationCremonesi, M., Ferrari, M. E., Bodei, L., Chiesa, C., Sarnelli, A., Garibaldi, C., Pacilio, M., Strigari, L., Summers, P. E., Orecchia, R., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4044-x · Cited by 141
Self-citation
Cited by
Radiation therapy‐associated toxicity: Etiology, management, and prevention
Wang, K., & Tepper, J. E. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21689 · Cited by 449
Advances in PET imaging of cancer
Schwenck, J., Sonanini, D., Cotton, J. M., Rammensee, H.-G., la Fougère, C., Zender, L., & Pichler, B. J. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00576-4 · Cited by 312
Kos‐Kudła, B., Castaño, J. P., Denecke, T., Grande, E., Kjaer, A., Koumarianou, A., de Mestier, L., Partelli, S., Perren, A., Stättner, S., et al. (2023) · Journal of Neuroendocrinology · doi:10.1111/jne.13343 · Cited by 256
Radiotheranostics in oncology: Making precision medicine possible
Aboagye, E. O., Barwick, T. D., & Haberkorn, U. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21768 · Cited by 131
Radiolabeled somatostatin analogs-a continuously evolving class of radiopharmaceuticals.
Fani, M., Mansi, R., Nicolas, G. P., & Wild, D. (2022) · Cancers · doi:10.3390/cancers14051172 · Cited by 56
Self-citationImaging glucose metabolism to reveal tumor progression
Meng, Y., Sun, J., Zhang, G., Yu, T., & Piao, H. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1103354 · Cited by 10
Metadata
- Authors
- Ambrosini, V., Kunikowska, J., Baudin, E., Bodei, L., Bouvier, C., Capdevila, J., Cremonesi, M., de Herder, W. W., Dromain, C., Falconi, M., Fani, M., Fanti, S., Hicks, R. J., Kabasakal, L., Kaltsas, G., Lewington, V., Minozzi, S., Cinquini, M., Öberg, K., Oyen, W. J. G., O'Toole, D., Pavel, M., Ruszniewski, P., Scarpa, A., Strosberg, J., Sundin, A., Taïeb, D., Virgolini, I., Wild, D., Herrmann, K., & Yao, J.
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 2021-03
- Volume
- 146
- Pages
- 56-73
- ISSN
- 0959-8049 (ISSN-L)
- OpenAlex
- W3133235753
- Cited by
- 244
- References
- 10
- FWCI
- 26.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.